Aptinyx, Inc., an Evanston, IL-based clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, completed a $70m Series B financing.
The round was led by Bain Capital Life Sciences with participation from new investors Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management, and Rock Springs Capital and existing investors New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O’Keefe & Company, and Northwestern University. In conjunction with the funding, Adam M. Koppel, M.D., Ph.D., a managing director of Bain Capital Life Sciences, has joined the Aptinyx board of directors.
The company intends to use the funds to advance its expanding clinical-stage pipeline. The funds will support clinical studies of Aptinyx’s drug candidates, including NYX-2925, in development for the treatment of neuropathic pain, and NYX-783, in development as a therapy for post-traumatic stress disorder (PTSD). The company also plans to advance a third proprietary compound into the clinic in 2018, initiate development programs in new indications, and continue discovery of additional novel, small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors.
Led by Norbert Riedel, Ph.D., president and chief executive officer, Aptinyx is currently conducting a Phase 2 study of NYX-2925 in patients with neuropathic pain associated with diabetic peripheral neuropathy (DPN), as well as an exploratory study in patients with fibromyalgia. The FDA has granted Fast Track designation to the development of NYX-2925 for neuropathic pain associated with DPN.
The company recently initiated a Phase 1 clinical study to evaluate the safety and tolerability of NYX-783 and intends to develop it for the treatment of PTSD, for which the FDA has granted Fast Track designation.
Aptinyx’s chemistry and discovery platform has generated numerous small-molecule modulators of the NMDA receptor, including clinical drug candidates NYX-2925 and NYX-783. In studies to date, these molecules have demonstrated high oral bioavailability, diverse NMDA receptor subtype binding profiles, differentiated efficacy across preclinical models of various nervous system conditions, and very favorable safety.